Table II.
Association between CD38/CD101 coexpression in PD-1+CD8+ T cells and clinical parameters of patients with ovarian cancer.
| PD-1+CD38+ CD101+ | PD-1+CD38− CD101− | ||||||
|---|---|---|---|---|---|---|---|
| Clinicopathological parameters | n | Low | High | P-value | Low | High | P-value |
| Age (years) | 0.537 | 0.537 | |||||
| <55 | 54 | 29 | 25 | 25 | 29 | ||
| ≥55 | 42 | 19 | 23 | 23 | 19 | ||
| Pathological grade | 0.101 | 0.220 | |||||
| Well/moderately differentiated (G1-G2) | 45 | 27 | 18 | 19 | 26 | ||
| Poorly differentiated (G3) | 51 | 21 | 30 | 29 | 22 | ||
| Tumor grade | 0.019 | 0.019 | |||||
| T1-T2 | 25 | 18 | 7 | 7 | 18 | ||
| T3-T4 | 71 | 30 | 41 | 41 | 30 | ||
| Lymph node metastasis | 0.002 | 0.038 | |||||
| N0 | 26 | 20 | 6 | 8 | 18 | ||
| N1 | 70 | 28 | 42 | 40 | 30 | ||
P-values were all calculated by the χ2 test. PD-1, programmed cell death-1.